Relative to other treatments to eradicate Helicobacter pylori, a low-dose rifabutin triple-therapy regimen does not lose efficacy in patients with a high body mass index, according to a post hoc controlled analysis.
Given previously published evidence that a high BMI is a risk factor for eradication regimen failure and that the majority of Americans are overweight or obese, these data are potentially meaningful to clinical practice, according to the investigators, led by John Y. Kao, MD, a